References
[1] Hindricks G, Potpara T, Dagres N, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS). Eur Heart J . 2020.
[2] Dagres N, Chao TF, Fenelon G, et al. European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) expert consensus on arrhythmias and cognitive function: what is the best practice? Heart Rhythm . 2018;15 : e37-e60.
[3] Islam MM, Poly TN, Walther BA, et al. Association Between Atrial Fibrillation and Dementia: A Meta-Analysis. Front Aging Neurosci . 2019;11 : 305.
[4] Kalantarian S, Stern TA, Mansour M, Ruskin JN. Cognitive impairment associated with atrial fibrillation: a meta-analysis.Ann Intern Med . 2013;158 : 338-346.
[5] Diener HC, Hart RG, Koudstaal PJ, Lane DA, Lip GYH. Atrial Fibrillation and Cognitive Function: JACC Review Topic of the Week.J Am Coll Cardiol . 2019;73 : 612-619.
[6] Silva R, Miranda CM, Liu T, Tse G, Roever L. Atrial Fibrillation and Risk of Dementia: Epidemiology, Mechanisms, and Effect of Anticoagulation. Front Neurosci . 2019;13 : 18.
[7] Moffitt P, Lane DA, Park H, O’Connell J, Quinn TJ. Thromboprophylaxis in atrial fibrillation and association with cognitive decline: systematic review. Age Ageing . 2016;45 : 767-775.
[8] Cheng W, Liu W, Li B, Li D. Relationship of Anticoagulant Therapy With Cognitive Impairment Among Patients With Atrial Fibrillation: A Meta-Analysis and Systematic Review. J Cardiovasc Pharmacol . 2018;71 : 380-387.
[9] Mongkhon P, Naser AY, Fanning L, et al. Oral anticoagulants and risk of dementia: A systematic review and meta-analysis of observational studies and randomized controlled trials.Neurosci Biobehav Rev . 2019;96 : 1-9.
[10] Friberg L, Rosenqvist M. Less dementia with oral anticoagulation in atrial fibrillation. Eur Heart J . 2018;39 : 453-460.
[11] Madhavan M, Hu TY, Gersh BJ, et al. Efficacy of Warfarin Anticoagulation and Incident Dementia in a Community-Based Cohort of Atrial Fibrillation. Mayo Clin Proc . 2018;93 : 145-154.
[12] Mavaddat N, Roalfe A, Fletcher K, et al. Warfarin versus aspirin for prevention of cognitive decline in atrial fibrillation: randomized controlled trial (Birmingham Atrial Fibrillation Treatment of the Aged Study). Stroke . 2014;45 : 1381-1386.
[13] Douiri A, McKevitt C, Emmett ES, Rudd AG, Wolfe CD. Long-term effects of secondary prevention on cognitive function in stroke patients. Circulation . 2013;128 : 1341-1348.
[14] Joe E, Ringman JM. Cognitive symptoms of Alzheimer’s disease: clinical management and prevention. BMJ . 2019;367 : l6217.
[15] Mongkhon P, Fanning L, Lau WCY, et al. Oral anticoagulant and reduced risk of dementia in patients with atrial fibrillation: A population-based cohort study. Heart Rhythm . 2020;17 : 706-713.
[16] Field TS, Weijs B, Curcio A, et al. Incident Atrial Fibrillation, Dementia and the Role of Anticoagulation: A Population-Based Cohort Study. Thromb Haemost . 2019;119 : 981-991.
[17] Nah MA, Lee KS, Hwang TY. Association Between Atrial Fibrillation and the Risk of Dementia in the Korean Elderly: A 10-Year Nationwide Cohort Study. J Prev Med Public Health . 2020;53 : 56-63.
[18] Krawczyk M, Fridman S, Cheng Y, Fang J, Saposnik G, Sposato LA. Atrial fibrillation diagnosed after stroke and dementia risk: cohort study of first-ever ischaemic stroke patients aged 65 or older.Europace . 2019;21 : 1793-1801.
[19] Ding M, Fratiglioni L, Johnell K, et al. Atrial fibrillation, antithrombotic treatment, and cognitive aging: A population-based study. Neurology . 2018;91 : e1732-e1740.
[20] Higgins J, Thomas J, Chandler J, et al. Cochrane Handbook for Systematic Reviews of Interventions version 6.0 (updated July 2019). Cochrane: Cochrane, 2019.
[21] Shamseer L, Moher D, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ . 2015;350 : g7647.
[22] Moher D, Shamseer L, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev . 2015;4 : 1.
[23] Pink J, O’Brien J, Robinson L, Longson D, Guideline C. Dementia: assessment, management and support: summary of updated NICE guidance. BMJ . 2018;361 : k2438.
[24] Berkman ND, Lohr KN, Ansari MT, et al. Grading the strength of a body of evidence when assessing health care interventions: an EPC update. J Clin Epidemiol . 2015;68 : 1312-1324.
[25] Wells G, Shea B, O’Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Ottawa Hospital Research Institute, 2014.
[26] Zhang J, Yu KF. What’s the relative risk? A method of correcting the odds ratio in cohort studies of common outcomes.JAMA . 1998;280 : 1690-1691.
[27] Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ . 2003;327 : 557-560.
[28] Friberg L, Andersson T, Rosenqvist M. Less dementia and stroke in low-risk patients with atrial fibrillation taking oral anticoagulation. Eur Heart J . 2019;40 : 2327-2335.
[29] Kim D, Yang PS, Yu HT, et al. Risk of dementia in stroke-free patients diagnosed with atrial fibrillation: data from a population-based cohort. Eur Heart J . 2019;40 : 2313-2323.
[30] Barber M, Tait RC, Scott J, Rumley A, Lowe GD, Stott DJ. Dementia in subjects with atrial fibrillation: hemostatic function and the role of anticoagulation. J Thromb Haemost . 2004;2 : 1873-1878.
[31] Marzona I, Baviera M, Vannini T, et al. Risk of dementia and death in patients with atrial fibrillation: A competing risk analysis of a population-based cohort. Int J Cardiol . 2016;220 : 440-444.
[32] Zhang C, Gu ZC, Shen L, et al. Non-vitamin K Antagonist Oral Anticoagulants and Cognitive Impairment in Atrial Fibrillation: Insights From the Meta-Analysis of Over 90,000 Patients of Randomized Controlled Trials and Real-World Studies. Front Aging Neurosci . 2018;10 : 258.
[33] Manolis TA, Manolis AA, Apostolopoulos EJ, Melita H, Manolis AS. Atrial Fibrillation and Cognitive Impairment: An Associated Burden or Burden by Association? Angiology . 2020;71 : 498-519.
[34] Rivard L, Khairy P, Talajic M, et al. Blinded Randomized Trial of Anticoagulation to Prevent Ischemic Stroke and Neurocognitive Impairment in Atrial Fibrillation (BRAIN-AF): Methods and Design.Can J Cardiol . 2019;35 : 1069-1077.
Table 1. Summary of findings of the effect of oral anticoagulant therapy on the risk of dementia